Inhibikase Therapeutics (NYSE:IKT) Downgraded to Neutral Rating by HC Wainwright

Inhibikase Therapeutics (NYSE:IKT) was downgraded by research analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research note issued to investors on Wednesday, Marketbeat.com reports.

Separately, Jefferies Financial Group initiated coverage on shares of Inhibikase Therapeutics in a report on Friday, November 8th. They issued a “buy” rating and a $8.00 target price on the stock.

Inhibikase Therapeutics Trading Down 4.1 %

NYSE:IKT opened at $2.34 on Wednesday. The firm has a market cap of $162.30 million, a price-to-earnings ratio of -0.88 and a beta of 1.06. The company’s 50-day moving average is $2.92 and its two-hundred day moving average is $2.17. Inhibikase Therapeutics has a 12-month low of $1.12 and a 12-month high of $4.20.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.